Home › Companies › AKERO THERAPEUTICS INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and AKERO THERAPEUTICS INC.’s Form 8-K, filed June 12, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 7, 2024: 6 items on AKERO THERAPEUTICS INC.’s Form 8-K, filed June 12, 2024: 4 passed (calculated) · 2 plurality election.
Significant dissent: 3 directors (69.6%, 67.5%, 35.8% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore AKERO THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are AKERO THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Seth L. Harrison, M.D. | 16,924,611 | -- | -- | 38,742,993 | 3,920,264 | 30% | Plurality election | — |
| Elect Director: Graham Walmsley, M.D., Ph.D. | 35,755,718 | -- | -- | 19,911,886 | 3,920,264 | 64% | Passed (calculated) | — |
| Elect Director: Yuan Xu, Ph.D. | 18,067,658 | -- | -- | 37,599,946 | 3,920,264 | 32% | Plurality election | — |
| Company's stockholders approved to ratify the appointment of Deloitte & Touche LLP in Proposal 2. | 59,238,349 | 37,608 | 311,911 | -- | 0 | 99.9% | Passed (calculated) | — |
| Company's stockholders approved, by non-binding advisory vote, the compensation of the Company's named executive officers in Proposal 3. | 52,835,974 | 2,548,327 | 283,303 | -- | 3,920,264 | 95% | Passed (calculated) | — |
| Company's stockholders approved an amendment to the Fourth Amended and Restated Certificate of Incorporation in Proposal 4. | 51,521,703 | 3,864,198 | 281,703 | -- | 3,920,264 | 93% | Passed (calculated) | — |
Source: AKERO THERAPEUTICS INC., Form 8-K, filed with the SEC on June 12, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
207 asset managers disclosed a vote on at least one AKERO THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
64% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors to serve until the 2027 annual meeting of stockholders and until his or her successor has been duly elected and qualified: Graham Walmsley, M.D., Ph.D
AKERO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Graham Walmsley, M.D., Ph.D.”): 35,755,718 for, 19,911,886 withheld, per its Form 8-K filed June 12, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 64% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 67 asset managers below reported 13,737,745 for, 9,486,537 withheld, 284,190 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,046,325 | 0 | 0 | 12,400 | For |
| T. Rowe Price | 0 | 0 | 0 | 3,875,162 | Withhold |
| BlackRock | 2,380,119 | 0 | 0 | 0 | For |
| State Street | 2,290,422 | 0 | 0 | 33,646 | For |
| JANUS INVESTMENT FUND | 191,879 | 0 | 0 | 1,911,454 | Mixed |
| Fidelity | 1,359,256 | 0 | 0 | 26,604 | For |
| AllianceBernstein | 0 | 0 | 0 | 521,101 | Withhold |
| Charles Schwab | 518,559 | 0 | 0 | 0 | For |
| Hartford | 489,288 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 0 | 0 | 460,936 | Withhold |
| ALGER INSTITUTIONAL FUNDS | 0 | 0 | 0 | 335,729 | Withhold |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 299,867 | Withhold |
| ALGER FUNDS II | 0 | 0 | 0 | 285,489 | Withhold |
| Principal | 152 | 0 | 0 | 279,402 | Withhold |
| Equitable | 94,715 | 0 | 0 | 184,134 | Mixed |
| ALGER FUNDS | 0 | 0 | 0 | 265,096 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 240,720 | Withhold |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 224,829 | 0 | Abstain |
| JPMorgan | 223,094 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 199,237 | Withhold |
| Artisan | 191,790 | 0 | 0 | 0 | For |
| John Hancock | 98,556 | 0 | 53,043 | 0 | Mixed |
| TIAA | 143,324 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 114,702 | 0 | 0 | 0 | For |
| Northwestern Mutual | 96,068 | 0 | 0 | 0 | For |
Showing the 25 largest of 67 asset managers. All 67 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
30% Plurality election · of votes cast
Description as filed by funds: Election of Class II Directors to serve until the 2027 annual meeting of stockholders and until his or her successor has been duly elected and qualified: Seth L. Harrison, M.D.
AKERO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Seth L. Harrison, M.D.”): 16,924,611 for, 38,742,993 withheld, per its Form 8-K filed June 12, 2024 (Item 5.07). This is a for/withhold election, which is decided by plurality: a nominee does not need a majority of the votes cast to be elected, so no passed or failed outcome is stated here.
Outcome: Plurality election — The company’s filing reports the vote counts but does not state the outcome; this is an election decided by plurality, so a nominee does not need a majority of the votes cast and no passed or failed outcome is calculated.
Support: 30% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 67 asset managers below reported 3,720,180 for, 19,097,539 withheld, 690,753 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,503,290 | 0 | 0 | 1,555,435 | Mixed |
| T. Rowe Price | 0 | 0 | 0 | 3,875,162 | Withhold |
| BlackRock | 0 | 0 | 0 | 2,380,119 | Withhold |
| State Street | 25,011 | 0 | 0 | 2,299,057 | Withhold |
| JANUS INVESTMENT FUND | 191,879 | 0 | 0 | 1,911,454 | Mixed |
| Fidelity | 0 | 0 | 0 | 1,385,860 | Withhold |
| AllianceBernstein | 0 | 0 | 0 | 521,101 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 518,559 | Withhold |
| Hartford | 0 | 0 | 0 | 489,288 | Withhold |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 0 | 0 | 460,936 | Withhold |
| ALGER INSTITUTIONAL FUNDS | 0 | 0 | 0 | 335,729 | Withhold |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 299,867 | Withhold |
| ALGER FUNDS II | 0 | 0 | 0 | 285,489 | Withhold |
| Principal | 0 | 0 | 0 | 279,554 | Withhold |
| Equitable | 0 | 0 | 0 | 278,849 | Withhold |
| ALGER FUNDS | 0 | 0 | 0 | 265,096 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 240,720 | Withhold |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 224,829 | 0 | Abstain |
| JPMorgan | 0 | 0 | 223,094 | 0 | Abstain |
| Aberdeen | 0 | 0 | 0 | 199,237 | Withhold |
| Artisan | 0 | 0 | 0 | 191,790 | Withhold |
| John Hancock | 0 | 0 | 151,599 | 0 | Abstain |
| TIAA | 0 | 0 | 0 | 143,324 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 114,702 | Withhold |
| Northwestern Mutual | 0 | 0 | 0 | 96,068 | Withhold |
Showing the 25 largest of 67 asset managers. All 67 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
32% Plurality election · of votes cast
Description as filed by funds: Election of Class II Directors to serve until the 2027 annual meeting of stockholders and until his or her successor has been duly elected and qualified: Yuan Xu, Ph.D
AKERO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Yuan Xu, Ph.D.”): 18,067,658 for, 37,599,946 withheld, per its Form 8-K filed June 12, 2024 (Item 5.07). This is a for/withhold election, which is decided by plurality: a nominee does not need a majority of the votes cast to be elected, so no passed or failed outcome is stated here.
Outcome: Plurality election — The company’s filing reports the vote counts but does not state the outcome; this is an election decided by plurality, so a nominee does not need a majority of the votes cast and no passed or failed outcome is calculated.
Support: 32% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 67 asset managers below reported 4,251,946 for, 18,841,706 withheld, 414,820 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,503,290 | 0 | 0 | 1,555,435 | Mixed |
| T. Rowe Price | 0 | 0 | 0 | 3,875,162 | Withhold |
| BlackRock | 0 | 0 | 0 | 2,380,119 | Withhold |
| State Street | 25,011 | 0 | 0 | 2,299,057 | Withhold |
| JANUS INVESTMENT FUND | 191,879 | 0 | 0 | 1,911,454 | Mixed |
| Fidelity | 7,281 | 0 | 0 | 1,378,579 | Withhold |
| AllianceBernstein | 0 | 0 | 0 | 521,101 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 518,559 | Withhold |
| Hartford | 0 | 0 | 0 | 489,288 | Withhold |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 0 | 0 | 460,936 | Withhold |
| ALGER INSTITUTIONAL FUNDS | 0 | 0 | 0 | 335,729 | Withhold |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 299,867 | Withhold |
| ALGER FUNDS II | 0 | 0 | 0 | 285,489 | Withhold |
| Principal | 0 | 0 | 0 | 279,554 | Withhold |
| Equitable | 0 | 0 | 0 | 278,849 | Withhold |
| ALGER FUNDS | 0 | 0 | 0 | 265,096 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 240,720 | Withhold |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 224,829 | 0 | Abstain |
| JPMorgan | 223,094 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 199,237 | Withhold |
| Artisan | 191,790 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 151,599 | 0 | Abstain |
| TIAA | 0 | 0 | 0 | 143,324 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 114,702 | Withhold |
| Northwestern Mutual | 0 | 0 | 0 | 96,068 | Withhold |
Showing the 25 largest of 67 asset managers. All 67 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: TO APPROVE AN AMENDMENT TO OUR FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, TO LIMIT THE LIABILITY OF CERTAIN OFFICERS OF AKERO THERAPEUTICS, INC., AS PERMITTED BY RECENT AMENDMENTS TO DELAWARE LAW.
AKERO THERAPEUTICS INC.’s own tally for this item (“The Company's stockholders approved an amendment to the Fourth Amended and Restated Certificate of Incorporation in Proposal 4.”): 51,521,703 for, 3,864,198 against, per its Form 8-K filed June 12, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 67 asset managers below reported 23,165,468 for, 332,802 against, 10,202 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,058,725 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,875,162 | 0 | 0 | 0 | For |
| BlackRock | 2,380,119 | 0 | 0 | 0 | For |
| State Street | 2,320,095 | 3,973 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,103,333 | 0 | 0 | 0 | For |
| Fidelity | 1,385,860 | 0 | 0 | 0 | For |
| AllianceBernstein | 521,101 | 0 | 0 | 0 | For |
| Charles Schwab | 518,559 | 0 | 0 | 0 | For |
| Hartford | 489,288 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 460,936 | 0 | 0 | 0 | For |
| ALGER INSTITUTIONAL FUNDS | 335,729 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 299,867 | 0 | 0 | 0 | For |
| ALGER FUNDS II | 285,489 | 0 | 0 | 0 | For |
| Principal | 279,554 | 0 | 0 | 0 | For |
| Equitable | 278,849 | 0 | 0 | 0 | For |
| ALGER FUNDS | 265,096 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 240,720 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 224,829 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 223,094 | 0 | 0 | Against |
| Aberdeen | 199,237 | 0 | 0 | 0 | For |
| Artisan | 191,790 | 0 | 0 | 0 | For |
| John Hancock | 151,599 | 0 | 0 | 0 | For |
| TIAA | 143,324 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 114,702 | 0 | 0 | 0 | For |
| Northwestern Mutual | 96,068 | 0 | 0 | 0 | For |
Showing the 25 largest of 67 asset managers. All 67 are in the interactive database (link above).
Combines 9 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Prior year: 96.8% for (June 23, 2023 meeting) ▼ 1.4 pts
Description as filed by funds: To consider and act upon a non- binding, advisory vote to approve the compensation of our named executive officers.
AKERO THERAPEUTICS INC.’s own tally for this item (“The Company's stockholders approved, by non-binding advisory vote, the compensation of the Company's named executive officers in Proposal 3.”): 52,835,974 for, 2,548,327 against, per its Form 8-K filed June 12, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,058,725 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,875,162 | 0 | 0 | 0 | For |
| BlackRock | 2,380,119 | 0 | 0 | 0 | For |
| State Street | 2,318,533 | 5,535 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,103,333 | 0 | 0 | 0 | For |
| Fidelity | 1,385,860 | 0 | 0 | 0 | For |
| AllianceBernstein | 521,101 | 0 | 0 | 0 | For |
| Charles Schwab | 518,559 | 0 | 0 | 0 | For |
| Hartford | 489,288 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 460,936 | 0 | 0 | 0 | For |
| Artisan | 435,859 | 0 | 0 | 0 | For |
| ALGER INSTITUTIONAL FUNDS | 0 | 335,729 | 0 | 0 | Against |
| AB DISCOVERY GROWTH FUND, INC. | 299,867 | 0 | 0 | 0 | For |
| ALGER FUNDS II | 0 | 285,489 | 0 | 0 | Against |
| Principal | 279,554 | 0 | 0 | 0 | For |
| Equitable | 278,849 | 0 | 0 | 0 | For |
| ALGER FUNDS | 0 | 265,096 | 0 | 0 | Against |
| Simplify Exchange Traded Funds | 0 | 0 | 0 | 263,354 | Withhold |
| Direxion Shares ETF Trust | 240,720 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 224,829 | 0 | 0 | 0 | For |
| JPMorgan | 223,094 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 199,237 | 0 | 0 | Against |
| John Hancock | 151,599 | 0 | 0 | 0 | For |
| TIAA | 143,324 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 114,702 | 0 | 0 | 0 | For |
Fund voting reports, all 68 managers: 22,551,509 for, 1,190,830 against, 263,354 withheld, 10,202 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Janus Henderson | 6,170,609 | 0 | 0 | 0 | For |
| GENERAL ATLANTIC, L.P. | 5,233,989 | 0 | 0 | 0 | For |
| T. Rowe Price | 5,105,551 | 0 | 0 | 0 | For |
| Wellington | 4,356,260 | 0 | 0 | 0 | For |
| State Street | 3,435,370 | 5,610 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 3,258,609 | 0 | 0 | 0 | For |
| BlackRock | 1,912,395 | 16,619 | 0 | 0 | For |
| Redmile Group, LLC | 1,858,702 | 0 | 0 | 0 | For |
| Boxer Capital, LLC | 1,676,733 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,445,179 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,414,136 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 1,299,888 | 0 | 0 | 0 | For |
| FRED ALGER MANAGEMENT, LLC | 59,703 | 1,199,976 | 0 | 0 | Against |
| Yiheng Capital Management, L.P. | 1,145,144 | 0 | 0 | 0 | For |
| ALKEON CAPITAL MANAGEMENT LLC | 1,072,051 | 0 | 0 | 0 | For |
| Logos Global Management LP | 800,000 | 0 | 0 | 0 | For |
| Charles Schwab | 535,310 | 0 | 0 | 0 | For |
| Northern Trust | 488,865 | 54 | 0 | 0 | For |
| EMERALD MUTUAL FUND ADVISERS TRUST | 424,901 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 337,555 | 0 | 0 | 0 | For |
| JPMorgan | 325,158 | 0 | 0 | 0 | For |
| EMERALD ADVISERS, LLC | 302,273 | 0 | 0 | 0 | For |
| Point72 | 278,048 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 268,491 | 0 | 0 | 0 | For |
| SILVERARC CAPITAL MANAGEMENT, LLC | 261,886 | 0 | 0 | 0 | For |
Institutional-manager reports, all 156 managers: 45,273,898 for, 1,935,963 against, 15,012 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.
AKERO THERAPEUTICS INC.’s own tally for this item (“The Company's stockholders approved to ratify the appointment of Deloitte & Touche LLP in Proposal 2.”): 59,238,349 for, 37,608 against, per its Form 8-K filed June 12, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 67 asset managers below reported 23,498,270 for, 10,202 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,058,725 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,875,162 | 0 | 0 | 0 | For |
| BlackRock | 2,380,119 | 0 | 0 | 0 | For |
| State Street | 2,324,068 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,103,333 | 0 | 0 | 0 | For |
| Fidelity | 1,385,860 | 0 | 0 | 0 | For |
| AllianceBernstein | 521,101 | 0 | 0 | 0 | For |
| Charles Schwab | 518,559 | 0 | 0 | 0 | For |
| Hartford | 489,288 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 460,936 | 0 | 0 | 0 | For |
| ALGER INSTITUTIONAL FUNDS | 335,729 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 299,867 | 0 | 0 | 0 | For |
| ALGER FUNDS II | 285,489 | 0 | 0 | 0 | For |
| Principal | 279,554 | 0 | 0 | 0 | For |
| Equitable | 278,849 | 0 | 0 | 0 | For |
| ALGER FUNDS | 265,096 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 240,720 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 224,829 | 0 | 0 | 0 | For |
| JPMorgan | 223,094 | 0 | 0 | 0 | For |
| Aberdeen | 199,237 | 0 | 0 | 0 | For |
| Artisan | 191,790 | 0 | 0 | 0 | For |
| John Hancock | 151,599 | 0 | 0 | 0 | For |
| TIAA | 143,324 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 114,702 | 0 | 0 | 0 | For |
| Northwestern Mutual | 96,068 | 0 | 0 | 0 | For |
Showing the 25 largest of 67 asset managers. All 67 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported.
| # | Asset manager | Shares voted |
|---|---|---|
| 1 | Vanguard | 5,058,725 |
| 2 | T. Rowe Price | 3,875,162 |
| 3 | BlackRock | 2,380,119 |
| 4 | State Street | 2,324,068 |
| 5 | JANUS INVESTMENT FUND | 2,103,333 |
| 6 | Fidelity | 1,385,860 |
| 7 | AllianceBernstein | 521,101 |
| 8 | Charles Schwab | 518,559 |
| 9 | Hartford | 489,288 |
| 10 | Advantage Advisers Xanthus Fund, L.L.C. | 460,936 |
| # | Asset manager | Shares voted |
|---|---|---|
| 1 | Janus Henderson | 6,170,609 |
| 2 | GENERAL ATLANTIC, L.P. | 5,233,989 |
| 3 | T. Rowe Price | 5,105,551 |
| 4 | Wellington | 4,356,260 |
| 5 | State Street | 3,440,980 |
| 6 | RTW INVESTMENTS, LP | 3,258,609 |
| 7 | BlackRock | 1,929,014 |
| 8 | Redmile Group, LLC | 1,858,702 |
| 9 | Boxer Capital, LLC | 1,676,733 |
| 10 | AllianceBernstein | 1,445,179 |
Shown as share counts, not percentages: no shares-outstanding figure has been matched to AKERO THERAPEUTICS INC. for the 2023-2024 season, so there is no denominator to divide by.
At AKERO THERAPEUTICS INC.'s shareholder meeting held June 7, 2024, in the 2023-2024 proxy season, 207 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 1,544 separate fund positions. On the most widely held item on that ballot — To consider and act upon a non- binding, advisory vote to approve the compensation of our named… — FOR was 95% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: AKERO THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
AKERO THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “AKERO THERAPEUTICS INC. 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/akero-therapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.